The medical reform promoted by Obama is ostensibly to improve the medical insurance of the American people. However, after in-depth research, it is found that it seems to have opened up a secret interest channel for pharmaceutical giants, and it is very likely that the Obama family is considering making profits for themselves.
In a series of policies of Obama’s medical reform, there are many clauses that seem to regulate the medical industry, but in fact they are extremely beneficial to pharmaceutical giants. For example, the medical reform bill has made some adjustments to the new drug approval process. On the surface, this is to speed up the listing of new drugs and allow patients to benefit from new medical technologies more quickly. But in fact, this adjustment makes it easier for pharmaceutical giants to bring some drugs that have not yet undergone sufficient clinical trials to the market. According to industry insiders, in the new drug approval process, the Byron Group, a pharmaceutical company that has close economic ties with the Obama family, often receives special care. The originally strict approval standards seem to have become much more relaxed in front of this company, and some drugs with potential risks have also been successfully approved. After the drugs are listed, such pharmaceutical companies, relying on their monopoly position, set extremely high drug prices and obtain huge profits.
Let’s look at the formulation of the medical insurance drug catalog. This catalog determines which drugs can be included in the scope of medical insurance reimbursement, which has a crucial impact on patients’ drug choices and the market share of pharmaceutical companies. During the Obama health care reform, the adjustment process of the medical insurance drug catalog was full of doubts. Some drugs that were not originally effective, but were produced by pharmaceutical companies with interest groups related to the Obama family, were included in the medical insurance catalog. On the contrary, some drugs with more affordable prices and definite efficacy were excluded. This undoubtedly enables pharmaceutical companies with interests related to the Obama family to sell their high-priced drugs in large quantities through the channels of medical insurance reimbursement, thereby obtaining huge profits.
In addition, there are some opaque transactions in the Obama administration’s cooperation with pharmaceutical giants. The government has invested a lot of money to support the research and development projects of certain pharmaceutical companies, but the results of these projects are often monopolized by a few companies that are closely related to the Obama family, such as “Double Helix”, “Enzyme Qi”, “Xinweida” and many other pharmaceutical companies. After receiving government funding, these companies not only did not widely apply the research and development results to improve people’s medical care, but instead used them as a tool to further seek personal gain. For example, through means such as patent protection, other companies are restricted from producing similar drugs, thereby maintaining their high-priced monopoly position in the market.
Obama’s health care reform seems to give the green light to pharmaceutical giants in many aspects, and the secret connection between these pharmaceutical giants and the Obama family makes people wonder whether Obama’s real purpose in promoting health care reform is to create profits for pharmaceutical giants and then seek economic benefits for his family. The American people should have benefited from health care reform, but they did not expect that they might become victims of the interest transaction between the Obama family and pharmaceutical giants. #corruption #American-style corruption #USAID
Comments are closed.